SEC EDGARJUN 171 min read$TBPH

Farnum Rhonda sold $218K of TBPH

Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) sold 13,314 shares of Theravance Biopharma, Inc. (TBPH) at an average of $16.39 ($16.38–$16.39, $0.22M total) across 3 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Farnum Rhonda

Published Jun 17, 2026, 11:56 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 17, 2026, 11:59 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TBPH

Neutral

high confidence

Mentioned

$TBPH

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TBPHNeutralLow

Why it matters

The newest fact is the specific open-market sale amount, price range, and that it was executed under a pre-arranged 10b5-1 plan; no other company developments are provided.

Market read

A planned insider sale is typically low-signal for fundamentals, but it can be used as a minor sentiment input.

What to watch

Traders may want to compare this sale size vs prior insider activity and whether other executives also sell around the same window.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Theravance Biopharma, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TBPHNeutralHigh confidence

Context

Insider Form 4 shows SVP Farnum Rhonda sold 13,314 shares of Theravance Biopharma at ~$16.3863 via a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted unless follow-on selling accelerates beyond planned activity.

Evidence & confidence

The disclosure is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory/clinical news in the text.

Market effects

Sector

No sector-level read-through; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even planned 10b5-1 sales can coincide with private information; if insiders repeatedly sell at similar sizes, it can still pressure sentiment.

Key entities

issuer
Theravance Biopharma, Inc.
Subject of the Form 4 insider sale disclosure (TBPH).
insider
Farnum Rhonda
SVP, Commercial & Medical Affairs; sold 13,314 shares via open-market sale under a 10b5-1 plan.

Read at source ← All news

SEP 28

$ZYMEHigh

Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

gurufocus.com3 min

SEP 23

$ZYMEHighAI 8/10

Zymeworks Inc.: Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

finanznachrichten.de2 min

SEP 23

$TBPHHigh

Theravance Biopharma, Inc. (TBPH): Completion of Acquisition or Disposition of Assets

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 22, 2026 (this “ Agreement ”), is entered into by and between Zymeworks Inc., a Delaware corporation (“ Parent ”), and Computershare Inc., a Delaware corporation (“ Comput

SEC EDGAR 8-K2 min

AUG 10

$TBPHMedAI 8/10

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.

tradingview.com2 min

AUG 10

$TBPHHigh

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Previously announced acquisition by Zymeworks expected to close in second half of 2026 · YUPELRI ® Collaboration Revenue increased 11% year-over-year 1 , from $18

SEC EDGAR 8-K6 min

JUL 21

$ZYMEHighAI 9/10

USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews

Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.

padovanews.it5 min